Aadi Bioscience Valuation

Is 3350 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 3350 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: 3350 (€2.08) is trading above our estimate of fair value (€0.35)

Significantly Below Fair Value: 3350 is trading above our estimate of fair value.


Key Valuation Metric

Which metric is best to use when looking at relative valuation for 3350?

Key metric: As 3350 is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for 3350. This is calculated by dividing 3350's market cap by their current revenue.
What is 3350's PS Ratio?
PS Ratio2.3x
SalesUS$25.07m
Market CapUS$54.72m

Price to Sales Ratio vs Peers

How does 3350's PS Ratio compare to its peers?

The above table shows the PS ratio for 3350 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average6x
2INV 2invest
8.2xn/a€63.2m
HPHA Heidelberg Pharma
12.6x16.6%€106.7m
MDG1 Medigene
2.8x13.3%€20.6m
CNW co.don
0.7xn/a€6.5m
3350 Aadi Bioscience
2.3x38.8%€54.7m

Price-To-Sales vs Peers: 3350 is good value based on its Price-To-Sales Ratio (2.3x) compared to the peer average (7.8x).


Price to Sales Ratio vs Industry

How does 3350's PS Ratio compare vs other companies in the DE Biotechs Industry?

6 CompaniesPrice / SalesEstimated GrowthMarket Cap
CNW co.don
0.7xn/aUS$6.97m
V9Z Aceragen
0.4xn/aUS$3.12m
PA8 Paion
0.2x30.2%US$2.78m
V9Z Aceragen
0.3x-161.8%US$2.18m
3350 2.3xIndustry Avg. 7.9xNo. of Companies6PS0612182430+
6 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Sales vs Industry: 3350 is good value based on its Price-To-Sales Ratio (2.3x) compared to the European Biotechs industry average (8x).


Price to Sales Ratio vs Fair Ratio

What is 3350's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

3350 PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio2.3x
Fair PS Ratio1.4x

Price-To-Sales vs Fair Ratio: 3350 is expensive based on its Price-To-Sales Ratio (2.3x) compared to the estimated Fair Price-To-Sales Ratio (1.4x).


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst 3350 forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
Current€2.08
€1.75
-16.0%
6.7%€1.86€1.63n/a2
Nov ’25€1.82
€1.47
-19.4%
7.7%€1.58€1.35n/a2
Oct ’25€1.82
€1.47
-19.4%
7.7%€1.58€1.35n/a2
Sep ’25€1.55
€5.14
+231.7%
101.5%€12.52€1.34n/a3
Aug ’25€1.41
€10.20
+623.5%
38.6%€12.98€4.64n/a3
Jul ’25€1.35
€10.20
+655.7%
38.6%€12.98€4.64n/a3
Jun ’25€1.61
€10.20
+533.6%
38.6%€12.98€4.64n/a3
May ’25€1.71
€10.72
+526.7%
41.0%€14.70€4.59n/a3
Apr ’25€2.18
€10.72
+391.6%
41.0%€14.70€4.59n/a3
Mar ’25€1.79
€10.70
+497.9%
41.0%€14.68€4.59n/a3
Feb ’25€1.67
€10.70
+540.8%
41.0%€14.68€4.59n/a3
Jan ’25€1.87
€10.70
+472.3%
41.0%€14.68€4.59n/a3
Dec ’24€4.74
€30.84
+550.5%
6.4%€33.64€28.03n/a4
Nov ’24€4.08
€33.66
+725.1%
16.3%€42.98€28.65€1.824
Oct ’24€4.62
€32.12
+595.2%
16.3%€41.00€27.33€1.824
Sep ’24€5.75
€32.12
+458.5%
16.3%€41.00€27.33€1.554
Aug ’24€4.78
€32.29
+575.4%
16.3%€41.22€27.48€1.414
Jul ’24€6.30
€32.29
+412.5%
16.3%€41.22€27.48€1.354
Jun ’24€7.40
€32.29
+336.3%
16.3%€41.22€27.48€1.614
May ’24€7.15
€36.46
+409.9%
17.0%€43.11€27.52€1.714
Apr ’24n/a
€36.67
0%
17.0%€43.36€27.68€2.184
Mar ’24€9.93
€39.61
+298.8%
17.2%€44.74€27.96€1.794
Feb ’24€11.39
€39.22
+244.4%
17.2%€44.30€27.69€1.674
Jan ’24€11.59
€41.05
+254.3%
17.2%€46.36€28.97€1.874
Dec ’23€12.59
€41.05
+226.0%
17.2%€46.36€28.97€4.744
Nov ’23€12.74
€42.22
+231.4%
18.6%€49.50€29.12€4.084

Analyst Forecast: Target price is lower than the current share price.


Discover undervalued companies